Cancer-associated thrombosis - treatment and prevention with direct oral factor Xa inhibitors

Venous thromboembolism (VTE) is a frequent cause of morbidity and mortality in patients with cancer. Moreover, management of VTE is frequently connected with complications, namely risk of recurrent VTE and bleeding. Low molecular weight heparins (LMWH) therapy administrated for 3-6 months is current...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Klinicka onkologie : casopis Ceske a Slovenske onkologicke spolecnosti 2021, Vol.34 (4), p.283
Hauptverfasser:	Grilusová, K, Bolek, T, Škorňová, I, Staško, J, Samoš, M, Mokáň, M
Format:	Artikel
Sprache:	eng
Schlagworte:	Administration, Oral Factor Xa Inhibitors - administration & dosage Factor Xa Inhibitors - therapeutic use Fibrinolytic Agents - administration & dosage Fibrinolytic Agents - therapeutic use Heparin, Low-Molecular-Weight - therapeutic use Humans Neoplasms - complications Pyrazoles - administration & dosage Pyrazoles - therapeutic use Pyridines - administration & dosage Pyridines - therapeutic use Pyridones - administration & dosage Pyridones - therapeutic use Rivaroxaban - administration & dosage Rivaroxaban - therapeutic use Thiazoles - administration & dosage Thiazoles - therapeutic use Thrombosis - drug therapy Thrombosis - etiology Thrombosis - prevention & control Venous Thromboembolism - drug therapy Venous Thromboembolism - etiology Venous Thromboembolism - prevention & control
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!